Precautions are Needed for COVID-19 Patients with Coinfection of Common Respiratory Pathogens

Introduction

At the beginning of December 2019, a cluster of “pneumonia of unknown etiology” emerged in Wuhan, Hubei Province, China. The disease has soon developed into an outbreak posing a pandemic threat. Since no causative pathogen was identified at the onset of the disease, it was once called “Wuhan pneumonia” by the health officials and the public. On December 31, 2019, a total of 27 cases were reported; meanwhile, a rapid response team led by the Chinese Center for Disease Control and Prevention (China CDC) was formed to conduct detailed epidemiologic and etiologic investigations in Wuhan [1-3]. After ruling out common respiratory pathogens such as influenza, avian influenza, respiratory syncytial virus (RSV), adenovirus (ADV), respiratory severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), etc., a novel coronavirus was confirmed as the etiological agent on January 7, 2020 and related disease was termed as Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO) [4]. Subsequent full-length genome sequencing analysis indicated that the newly discovered virus, now known as severe acute respiratory coronavirus 2 (SARS-CoV-2), belongs to a distinct beta-coronavirus genus of probable bat origin [5, 6]. Thus far, the epidemic has swept through the nation. As of February 29, 2020, the number of laboratory or clinical confirmed cases in China has increased to approximately 80,000, causing over 2,800 death [7]. The fast-growing outbreak has affected over fifty countries and regions including Hong Kong, Vietnam, South Korea and the USA [8-10], constituting a public health emergency of international concern [11].

Surprisingly, we found a large proportion of coinfection with other seasonal respiratory pathogens in COVID-19 patients admitted to hospitals in Qingdao, Shandong Province, northeast China, which differed from those of the primary infected patients from the epidemic center, Wuhan, central China [3, 12]. To determine such between-region difference and to explore the possible reasons behind it, we conducted this double-center study recruiting COVID-19 patients admitted in both Qingdao and Wuhan hospitals. We hope our study will provide a new perspective on prevention and management of COVID-19 patients and to facilitate a better understanding of the disease.

Methods

Study areas

We chose Qingdao and Wuhan as the study centers to investigate the difference in coinfection with common respiratory pathogens among COVID-19 patients. Figure 1 showed the geographical location of two cities. As depicted, Qingdao is situated about 850 kilometers northeast of Wuhan.

• Download figure
• Open in new tab

Figure 1.

Geographical location of Qingdao and Wuhan, China

Results

By February 16, 2020, a total of 68 patients with laboratory-confirmed SARS-CoV-2 infection was included in the final analysis, among whom 30 were from Qingdao and 38 were from Wuhan (Table 1). The median age of Qingdao and Wuhan patients were 50 years (IQR: 37-59) and 31 years (IQR: 28-38), respectively. The median duration from symptom onset to hospitalization was 2.0 days (IQR: 0.0-5.0) for patients in Qingdao and 4.0 days (IQR: 2.0-5.0) for that in Wuhan. The majority of patients admitted in Qingdao and Wuhan hospitals were female, representing a proportion of 60.00% and 55.26%, respectively. The most common symptoms at onset of COVID-19 were fever (66.67% vs. 57.89%) and cough (50.00% vs. 68.42%) in both Qingdao and Wuhan patients. Over one third of the Qingdao patients had underlying diseases (36.67%), a proportion much higher than that of Wuhan patients (2.63%). In comparison with Wuhan patients, Qingdao patients were older, had a higher respiratory rate (20 breaths/min [IQR: 19-21] vs. 19 breaths/min [IQR: 18-20]) and increased diastolic blood pressure (77 mmHg [IQR: 70-84] vs. 72 mmHg [IQR: 70-77]; all P values less than 0.05). On admission, white blood cell and platelet counts of Qingdao patients were higher than those of Wuhan patients (median white blood cell count: 5.11×10⁹/L [IQR: 4.15-6.10] vs. 4.17×10⁹/L [IQR: 3.50-5.60], P=0.0401; median platelet count: 237×10⁹/L [IQR: 165-265] vs. 166 × 10⁹/L [IQR: 148-207], P=0.0043). The median total bilirubin level was 12.50 μmol/L (IQR: 10.50-15.50) in Qingdao patients, which was significantly higher than that in Wuhan patients (7.14 μmol/L [IQR: 5.70-9.70], P=0.0016).

All patients had respiratory specimens tested for specific IgM antibodies against IFV-A, IFV-B, RSV, ADV, PIV, MP, LP, CP and COX. Among the 30 patients admitted in Qingdao, 24 patients had IgM antibodies detected against at least one of the above-mentioned pathogens, and the overall positive rate was 80.00% (Table 3); whereas only one (2.60%) of the patients in Wuhan had positive results for respiratory pathogens. The most common respiratory viruses detected were IFV-A (60.00%) and IFV-B (53.33%), followed by MP (23.33%) and LP (20.00%).

Ages of the healthy control group ranged from 20 to 55 years, with a median age of 40 years (IQR: 33-50), and 14 (46.67%) were men. Only 4 people (13.33%) of this group had specific-IgM antibody detected in their serum, suggesting asymptomatic infection with single virus (IFV-B). The total infection rate in healthy control was significantly lower than that in COVID-19 patients (P<0.0001, Table 4), and none of the normal individual in control group had combined infection.

Figure 2 showed the rate of coinfection with other respiratory pathogens detected in Qingdao COVID-19 patients as compared with CAP controls. The overall positive rate for coinfection in CAP group was 20.90%, significantly lower than the figure in COVID-19 patients (80.00%, P=0.0055). Except for SARS-CoV-2, 7 (23.33%) COVID-19 patients had mixed infections of IFV-A and IFV-B, 6 (20.00%) patients of this group had 3 respiratory pathogens (IFV-A, IFV-B and MP/LP) detected, and 13.33% of them had combined infection of IFV-B only. Whereas in CAP group, patients were more often coinfected with IFV-B and MP (8.96%), followed by a combination of IFV-A and MP (4.48%), and IFV-A and RSV (2.99%). Thus it can be seen that COVID-19 patients had distinct etiological features of coinfection from CAP patients in Qingdao.

• Download figure
• Open in new tab

Figure 2.

Rate of coinfection with common respiratory pathogens in COVID-19 and CAP patients in Qingdao

Table 5 showed the climatic characteristics of Qingdao and Wuhan from December to January of following year, where differences could be observed between the two cities. Although the climate in Qingdao is drier and colder than Wuhan, major respiratory pathogens circulate in the two cities were quite similar.

Discussion

This is an extended descriptive study on COVID-19 patients between Wuhan and Qingdao, represented as within and beyond the epidemic center, respectively. Since the early onset of COVID-19 till the specific definition of novel coronavirus (previously known as 2019-nCoV) releasing on January 7, 2020 [4], the term “illness/pneumonia of unknown etiology” was repeatedly quoted by the health officials and the public during this one-month period. One of the possible explanations for such failure to clearly define the disease is that no causative pathogen could be found at the early stage. We speculated that if any common respiratory pathogen, such as influenza and parainfluenza viruses, RSV, ADV, MP and CP, or the previous emerging novel coronaviruses including SARS-CoV and MERS-CoV, was isolated from body fluids and secretions of the infected patients, related treatment and management could have been implemented in the first place. As such, it was very unlikely that “pneumonia of unknown causes” would still be emphasized, although this might cause delay in the discovery of SARS-CoV-2. Therefore, we assumed that the possibility of coinfection in COVID-19 patients was very rare. Our assumption was led support by two recent studies conducted in Wuhan showing that there was no coinfection of respiratory pathogens in COVID-19 cases [3, 12].

According to our data, the vast majority of COVID-19 patients in Qingdao were not from the endemic area; they were infected indirectly without a history of traveling to Wuhan. Despite the high coinfection rate in COVID-19 patients in Qingdao, there are no signs of worsening of these patients’ clinical manifestations or prognosis of the disease. A study conducted in Zhejiang Province, China revealed that COVID-19 patients outside of Wuhan had relatively mild symptoms as compared with those initially reported in Wuhan [16]. Like patients in Qingdao, these Zhejiang patients had no direct contact with the original site of outbreak (Wuhan Huanan Seafood Market). Evidence is scarce at the present stage to explain whether it is due to the weakening of SARS-CoV-2 virulence during virus transmission. Previous studies on SARS have shown that the disease was more infectious at an earlier stage when compared to the later stage [17]. The global mortality rate of MERS was about 40% and declined sharply to less than 20% during second generation transmission [18]. Currently, our first priority is to slow transmission of SARS-CoV-2. Some of the patients are still under hospitalized treatment or under isolation, requiring a multidisciplinary approach to illustrate the underlying mechanisms in the future.

Here we also compared the geographical and climatic characteristics of Qingdao and Wuhan. Wuhan is located in the center of southern China and has a subtropical climate [19, 20]; while Qingdao is situated in the coastal area of northern China in the temperate zone, which has a relatively lower humidity than Wuhan [21]. Despite the difference in natural characteristics between the two cities, common respiratory pathogens circulate in Wuhan and Qingdao Wuhan (including IFV-A, IFV-B, RSV, and ADV) have shown to be generally similar during the peak season of respiratory diseases in wintertime (from January to February) [22-25]. The incidence of coinfection in COVID-19 patients in Wuhan was rather low. However, in places with relatively low temperature like northern Qingdao, it is more common to find combined SARS-CoV-2 infection with other seasonal respiratory pathogens. It is still unclear whether this phenomenon also exists in other regions, leaving a gap for future studies. There are limited data to address whether coinfection with other respiratory viruses would affect the pathogenesis and outcome of severe acute respiratory illnesses like SARS and MERS [26-30].

Fortunately, all of our patients were found to have SARS-CoV-2 infection before coinfection being detected. Otherwise these COVID-19 patients would have been treated in the way as infected with other respiratory pathogens, which might result in devastating consequences. Our findings provide some important implications for the prevention and management of COVID. First of all, it is very effective and efficient for the China CDC and local governments to launch series of aggressive measures to screen, monitor, isolate, diagnose, and treat suspected patients and their close contacts in response to the widespread transmission of the virus. Moreover, we must remain vigilant when dealing with COVID-19 cases in other locations outside of Wuhan. Even common respiratory pathogens are detected by diagnostic testing, we still need to rule out the possibility of SARS-CoV-2 infection. In light of the emergence of coinfected COVID-19 cases, there might be a long-term coexistence of SARS-CoV-2 with humans, just as other seasonal respiratory pathogens. Last but not least, we highly recommend adding SARS-CoV-2 to the clinical testing assay as soon as possible, in a manner as how we routinely detect influenza and parainfluenza viruses, RSV, ADV, MP and CP, etc. Our hospitals adopted the above-mentioned screening and surveillance protocol right after the recognition of first coinfected COVID-19 case. Further detailed investigations should aim to ascertain the exact reasons underlying the high coinfection rate outside of Wuhan.

It is notable that there are several limitations of this study. Two critically ill patients and one patient who died in the end were excluded due to lack of etiological data other than SARS-CoV-2. As of February 16, 2020, there were 60 cases of confirmed SARS-CoV-2 infection in Qingdao, however, we only analyzed 30 non-severe cases whose complete etiological and clinical information was available. The age of patients in Qingdao ranged from 1.5 years to 80 years; whereas patients in Wuhan were all adults as they were medical staff infected in the hospital. Such age difference between the two groups might bring in bias to this study. We performed nucleic acid testing for the confirmation of SARS-CoV-2 infection, while coinfection with other pathogens was detected by serological testing of antibodies. In spite of superior accuracy, PCR-based molecular testing requires more complicated techniques of laboratory personnel with prolonged reporting time, which may not be suitable for emerging cases of SARS-CoV-2 [31, 32]. Thus, we applied rapid testing of etiological agents by IIF to guide clinical decision making. Since both the hospitals in Qingdao and Wuhan adopted the same protocol for the diagnosis of coinfections, we believe this will not affect the determination of final outcomes. To test the reliability of serum specific IgM detection, we recruited a control group of normal people without clinical symptoms. The low infection rate in our control population suggested that our method was reliable in early and rapid diagnosis of respiratory infections. However, we were unable to exclude the possibility that coinfection with other respiratory pathogens may make the patients more susceptible to SARS-CoV-2 infection. Specific-IgM antibody could be detected within one week after onset of infection and can last for 1-3 months in the serum [33]. Positive results for serum IgM antibody detection only indicate infection with specific pathogens during the past one to two months, but cannot tell the time sequence of coinfection with various pathogens. Whether immune regulation associated with earlier infection with common respiratory pathogens confers an element of protection against the pathological damage caused by subsequent infection of SARS-CoV-2 remains unanswered.

Till now, the epidemic is still expanding with the number of infected patients escalating rapidly, and the situation in countries and regions beyond China presents a more dismal picture. Recently, WHO upgraded the risk assessment of SARS-CoV-2 to very high; as of 28 February 2020, a total of 4,351 cases in 49 countries, and 67 deaths have been reported outside China [11]. Hence, we call for a timely action to carry out real-time research on the epidemic dynamic of SARS-CoV-2.